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Abstract 
0. ABSTRACT 
 
Veterinary drugs are therapeutically used for laying hens but may also reach them 
unintentionally via the feed e.g. as a result of cross-contamination during premix 
manufacture, feed preparation in the feed mill or during feed transport.  
When these compounds reach the bloodstream, they will occur in the ovary with 
growing follicles and the oviduct, where the egg white is formed and secreted. The 
deposition of drugs in either yolk or white or both phases determines where one 
should look for residues.  
Three reasons might rule the distribution of drugs between egg yolk and egg white:  
lipid solubility as fat soluble compounds generally occur in yolk, pKa value as ionised 
molecules will distribute in a certain way between phases with different pH values 
such as yolk and white or protein binding to egg white proteins.  
An extensive survey of available literature data on residues in egg yolk and white 
after administration to laying hens was made. The data on the distribution of residues 
between yolk and white differ considerably between drugs, but show remarkable 
resemblance for data on a given drug. All data on sulfonamides as well as on 
tetracyclines were considered carefully for any relationship between physicochemical 
characteristics and residue data in yolk and white. The lipid solubility hypothesis was 
certainly not supported by the available data including own previous experiments.  
All three explanations have also been tested in two animal experiments in which 
several sulfonamides differing in lipid solubility, pKa value and protein binding were 
administered to laying hens via the feed during 14 days and the levels in both yolk 
and egg white measured. 
None of the three reasons could satisfactorily explain the ratio of the sulfonamide 
residues in egg white and yolk found in these experiments. 
The conclusion therefore is that  at least for the sulfonamides tested  egg yolk and 
egg white are not two phases separated by a semi-permeable membrane and in 
some way in equilibrium with each other.  
Rather, two independent physiological processes in the laying hen govern the 
deposition of residues of the sulfonamides in egg yolk and egg white. 
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1. INTRODUCTION  
 
Veterinary drugs are therapeutically used for laying hens, generally by mass 
application via water or feed in order to combat occurring diseases. Drugs or 
coccidiostats may also reach them unintentionally via the feed e.g. as a result of 
cross-contamination during premix manufacture, feed preparation in the feed mill or 
during feed transport.  
Some of the drugs are designed to work systemically; thus they must cross the 
intestinal wall in order to exert their function. Other drugs  and certainly those that 
combat endoparasites such as coccidiostats  should exert their action within the 
gastro-intestinal tract but they are nevertheless (partly) absorbed. This absorption is 
quite logical as both veterinary drugs and coccidiostats possess certain lipophilic 
properties in order to interact with and pass through membranes. These lipophilic 
properties are a prerequisite to reach target organs or cells and to fulfil their task of 
eliminating micro-organisms, coccidia or other endoparasites. 
When these compounds reach the bloodstream, they will be distributed over the 
whole body. In the laying hen this includes also the ovary with growing follicles and 
the oviduct, where the egg white is formed and secreted. The amount of the 
compounds or its metabolites in each tissue depends on their characteristics, such 
as differences in rate of metabolism or lipid solubility. 
Knowledge about the deposition of drugs in either yolk or white or both is required for 
at least three reasons: 
1. To know whether either the white or the yolk might still be safe for human 
consumption in case residues are found in whole egg 
2. To know whether yolk or white or both should be sampled to correctly assess the 
residue content of whole eggs 
3. To develop drugs with special properties to target specifically either yolk or white 
if required.  
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1.1 Formation and composition of the egg 
 
The main components of the avian egg are: egg shell, white and yolk. Figure 1 gives 
a schematic drawing of the egg and its components.  
The follicles  later becoming the yolks - grow on the ovary and after ovulation the 
free ovum is picked up by the infundibulum (Figure 2) of the oviduct and then 
transported towards the albumen secreting region or magnum (Figures 2 and 3). 
 
 
Figure 1: Components of the egg (Gilbert 1971a)  
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Figure 2: The reproductive tract of the hen (Nesheim et al., 1971) 
Figure 3: Processes occurring during egg formation (Gilbert 1971b) 
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Via the isthmus, where the membranes are formed, the egg then enters the shell 
gland or uterus. There, fluid and minerals are added during the plumping process to 
the egg white and the shell is formed. Then the ready-to-lay egg is transported via 
the vagina and through the cloaca (Figure 2), and the egg is laid. The time frame of 
the whole process is outlined in Figure 4.  
  
  
Figure 4: Time schedule of egg formation  (Gilbert 1971a) 
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1.2 Formation of 
 
1.2.1 Follicles or Yolk 
Yolk components (pre-dominantly lipoproteins) are formed in the liver and 
transported via the blood to the ovary. The ovary of hens in active production 
(Figure 2 and 8) contains three types of follicles where the yolk can be deposited: 
1. Very small ones, in the slow phase of development which can take months or 
even years. These are also called the white follicles as no (coloured) 
carotenoids are deposited there. 
2. Those in the intermediate phase of growth (lasting some 60 days) 
3. Follicles in the rapid growth phase which lasts approximately 10 days. The 
follicle weight increases during this time from some 1 gram to about 20 grams 
and deposition occurs in concentric layers one after each other (Figures 5, 6 
and 7).  
Figure 5: Growth curve of the follicles (Gilbert 1972) 
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Figure 6: Yolk deposition schematically 
 
Figure 7: Yolk deposition as pictured by MRI (Donoghue and Myers, 2000) 
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As one follicle ovulates approximately every 24 hours, roughly ten follicles are 
present in different stages of the rapid growth. Figure 8 (Donoghue and Myers, 2000) 
shows the ovary with follicles as can be found in hens in active production and the 
separate yolks. 
 
 
 
Figure 8: Ovary and separate yolks (Donoghue and Myers, 2000) 
 
It is not well known, whether yolk material deposition carries on right until the 
moment of ovulation or that one day elapses between last deposition of yolk material 
and ovulation. 
The physiological and endocrinological processes probably taking place before 
ovulation are schematically shown in Figure 9. 
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Figure 9: Time schedule of ovulation (Gilbert 1971a) 
LH = Luteinizing Hormone; FSH = Follicle Stimulating Hormone 
 
A more detailed description of the total physiology of egg formation and laying 
can be found in various textbooks on poultry physiology e.g. Bell & Freeman 
(1971)  
 
1.2.2 Egg white 
The (water-soluble) proteins are formed in and secreted by one part of the oviduct 
called the magnum. Formation of the proteins takes 1-2 days and deposition of 
egg white around the yolk at some 2-3 hours after ovulation (Figure 3) 
 
1.2.3 Shell membrane and shell 
Shell membranes are formed at some 3-4 hours after ovulation (Figure 4) and 
finally addition of water and salts (plumping) (Figures 2 and 3) and the 
deposition of the (calciumcarbonate) eggshell (Figures 1 and 4) takes place in 
about 18-20 hours (Bell & Freeman, 1971).  
 
The time schedule as outlined in Figure 4 has been deducted many years ago 
when egg production was much lower than presently achieved by high productive 
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hens. Therefore, it is not certain that at present this time schedule is still totally 
accurate.  
 
1.3 Residues in egg white and yolk 
 
Due to the physiological processes described above, the pharmacokinetics of drug 
residues in yolk and egg white show the following features: 
1. Residues of drugs appear first in egg white, at least when the drug is distributed 
towards that compartment (Donoghue et al., 2000). 
2. Residues in egg white are a reflection of drug plasma levels and will therefore 
show a constant level over time when plasma levels do. The time needed to 
achieve a constant drug level in egg white is generally 2-3 days.  
3. Residues in yolk reflect the plasma drug levels during the ten days of their rapid 
growth. Thus depending on the length and time of exposure to the drug relative to 
yolk growth, drug levels in yolk  when measured during a number of consecutive 
days -can increase, be constant or decrease. 
4. Residues of drugs in yolk generally require exposure for about 8 - 10 days to 
reach a constant level. 
5. A single exposure towards a drug might be sufficient to detect the drug in either 
egg white or yolk (Donoghue et al., 1998), depending on the characteristics of the 
drug and the sensitivity of the analytical method used. 
6. Disappearance of drugs from white and yolk depends heavily on the plasma 
levels of the drug tested. Drugs that clear rapidly from the body also disappear 
from egg white in about 2-3 days after cessation of exposure. Disappearance of 
drugs from yolk generally takes about 10 days. By that time, drug-containing 
lipoproteins deposited during the rapid growth phase of the yolk have been 
excreted with the eggs.  
7. However, if the exposure level is very high and the detection limit for the drug 
involved is very low, then residues deposited in the yolks, which are in the 
intermediate stage of growth, will also be detectable. This can explain the 
observation, that Arnold & Somogyi (1986) found chloramphenicol residues in 
eggs until 70 days after administration.  
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8. On the other hand, if the limit of detection of the method is similar to the drug 
residue levels in the egg, residues may not be detected at all or only during a very 
short time period.  
Microbiological methods, which measure the unbound fraction of antimicrobial 
drugs only, may for that reason indicate lower residue levels than methods  
such as those using HPLC - which measure also the amount absorbed to protein 
as the organic solvent used to extract the drug, generally breaks up this type of 
binding.  
 
Both Anhalt (1977) and Hafez (1991) consider the egg yolk to be the main 
compartment of eggs to be taken into account when considering drug residues. This 
in contrast to the observations of Blom (1975)  quoted by both authors  who 
reported much higher residues of some sulfonamides in egg white than in egg yolk.  
Recently Donoghue et al. (2000) showed that transfer of drugs  or at least 
oxytetracycline  into egg white also occurs during the plumping phase. This had 
been anticipated to be found, as we observed several times, that drugs administered 
to the hens in the afternoon led to residues in the eggs laid the next day. This could 
only occur if transfer of the drug into the white during the plumping phase happened.  
In addition Furusawa (1999) detected the presence of spiramycine, oxytetracycline 
and sulfamonomethoxine in both the isthmus and magnum part of the oviduct. 
 
1.4 Available data on drug levels in egg white and yolk 
 
The data found in the literature from experiments where exposure was sufficiently 
long to expect a constant residue level in egg white and yolk and from own studies 
that have not been published are summarised in Table 1. They sometimes are 
(educated) guesses from either graphs or tables made on steady state levels and 
may deviate from the data in the original papers.  
 
1.5 General observations on the distribution data 
 
Sulfonamides show appreciable levels in both egg white and yolk and levels in egg 
white are at least equal to those in yolk, but often they are (much) higher.  
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Tetracyclines as a group show a more divergent picture. Remarkably some very 
lipophilic ones (doxycycline and minocycline) show higher levels in egg white than in 
(the fat rich) yolk. On the contrary the more water soluble oxytetracycline and 
chlortetracycline show similar levels in white and yolk. 
The quinolones flumequine, oxolinic acid and enrofloxacine also show much higher 
residues in egg white than in yolk. 
Many other substances such as macrolides and nitrofurans show diverging patterns 
of distribution, but in all instances, levels in egg white are substantial. 
Some compounds like trimethoprim, pyrimethamine, amprolium, nicarbazine, 
decoquinate, dinitolmide, and ivermectin occur almost exclusively in yolk and show 
very low levels in egg white.  
 
1.6 Possible explanations 
 
The physicochemical properties of drugs largely determine their pharmacokinetics.  
Martinez (1998) in a review mentions the following factors influencing drug kinetics in 
animals:  
• molecular weight: too bulky molecules not being able to cross membranes,  
• lipid solubility as measured by the octanol/water partition coefficient   
• pKa value, which determines whether a molecule is ionised at a certain pH, as 
according to some theories only unionised compounds would penetrate biological 
membranes. 
• protein binding to plasma proteins as it determines availability to other 
compartments,  
 
Hafez (1991) in his review makes a distinction between drug factors, bird factors and 
analytical method factors. Drug factors deal with metabolism that includes 
absorption, distribution, biotransformation and excretion. The bird factor focuses on 
the yolk as the drug-containing compartment of eggs and pays little attention to 
residues in egg white. Regarding analytical factors he emphasises variation in 
sensitivity within substances between methods and between substances within 
methods. The possibility of false positive results, both in microbiological and chemical 
methods, due to natural substances or contamination after sampling is also 
mentioned. 
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Anhalt (1977) largely concentrates on yolk deposition processes in relation to drug 
residues in eggs and treats the possibility of residues in egg white as a minor issue. 
 
1.6.1 Lipid solubility 
Lipid solubility of the drug certainly influences its deposition in the (fat rich) 
yolk (Blom, 1975) but higher residues of (the lipophilic) doxycycline in egg 
white than in yolk (Table 1) can not be explained in this way. Nevertheless 
Furusawa (1999) states  The drugs having the property of lipid-solubility are 
found in much higher levels in egg yolk than in albumen, whereas those 
having water-solubility are found in higher concentrations in albumen than in 
egg yolk. However, he also admits (Furusawa personal communication, 2000) 
that it can not be the only determining factor. 
Gorla et al. (1997) consider the possibility that differences in lipid solubility due 
to a different chemical structure may alter intracellular penetration and thus 
explain the patterns of distribution they observed for enrofloxacine end 
ciprofloxacine between yolk and egg white. As ciprofloxacine is a metabolite of 
enrofloxacine (and thus generally better water-soluble) their observation that 
ciprofloxacine is predominantly present in yolk, does not concur with this 
explanation. 
 
1.6.2 Partitioning between phases with different pH 
The pH of yolk is around 6.0 when the egg is just laid and that of egg white at 
that time is 7.6. Distribution of drugs between compartments with different pH 
values according to their pKa values has been established for a number of 
different combinations of compartments. Distribution of drugs between plasma 
and gastric juice was e.g. explained by Shore et al. (1957), distribution 
between plasma and cerebrospinal fluid by Rall et al. (1959) and intestinal 
absorption of drugs by Hogben et al. (1959). Schanker et al. (1964) 
established it for passage of drugs into red cells and Atkinson and Begg 
(1990) predicted in this way the distribution of drugs between plasma and milk.  
Blom (1975) compared distribution of three sulfonamides between plasma and 
egg white with the pKa values of those drugs and could not draw an 
unambiguous conclusion whether or not this hypothesis should be accepted. 
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1.6.3 Protein binding 
Roudaut (1998) considered protein binding to be a possible explanation for the 
observed distribution of oxolinic acid between egg white and yolk. Gorla et 
al.(1997) considered the same possibility for the related compounds 
enrofloxacine and ciprofloxacine.  
Blom (1975) measured protein binding of three sulfonamides and 
pyrimethamine in plasma and egg white both in vitro and in vivo. Sulfadimidine 
had the lowest binding percentage (some 10 %) and sulfaquinoxaline the 
highest (some 50 % in egg white). The ratio of residues in egg white and yolk 
did however not differ in the same way in that study (Table 1). Furusawa 
(Personal communication, 2000) considers protein binding and especially the 
rate of binding and the amount of binding material of major importance for 
distribution of a drug within body or egg. 
As to binding of drugs to yolk or to yolk macromolecules, Blom (1975) testing 
sulfonamides and Kan and Rump (unpublished observations on tetracyclines) 
were not able to find a satisfactory methodology. 
 
1.6.4 Other 
Riberzani et al. (1993) suggested that the much higher levels of flumequine in 
egg white than in yolk might be caused by the high solubility of the acid drug 
flumequine in the basic matrix egg white. Roudaut (1998) studying the related 
compound oxolinic acid also considered this a possibility to explain higher 
levels of both oxolinic acid and sulfadimidine in egg white than in yolk. 
Diffusion from yolk to white during storage as suggested by Geertsma et al. 
(1987), was ruled out by Roudaut (1998) as eggs where separated 
immediately after laying.  We also compared (Kan and Rump, unpublished 
observations) the distribution of doxycycline in eggs in experiments with direct 
separation of egg white and yolk to experiments with prolonged storage of 
whole eggs and found no differences in distribution patterns. Exchange of 
drugs between yolk and egg white during egg formation  especially during the 
18 hours of shell deposition at a body temperature of 41 0C  can however not 
be ruled out. In line with this option, Gorla et al. (1997) consider diffusion a 
possibility to explain the observed distribution of enrofloxacine between yolk 
and egg white 
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Botsoglou et al. (1989) ascribe the different distribution of furazolidone 
between yolk and egg white to the dissimilarity in their mode of formation in 
respect to the time frame: this time of formation being much longer for yolk 
than for egg white. This explanation might be true for drugs like furazolidone 
showing higher levels in yolk, but it can not explain how levels of certain drugs 
in egg white can be higher than their levels in yolk.   
 
1.6.5 Other remarkable points 
Roudaut and Boisseau (1990) could detect residues of oxolinic acid in egg 
white much longer than in plasma and somewhat longer than in yolk. This is 
not compatible with the theory mentioned above (Paragraph 1.3) that the 
levels in egg white are a reflection of levels in plasma. Also the general rule 
that residues are detectable longer in yolk than in white is not followed here. 
Van Leeuwen and van Gend (1989) observed that levels of the related 
compound flumequine also persisted longer in egg white than in yolk. The 
results of these two studies suggest that quinolones might have special 
characteristics in combination with egg white (proteins).  
Furusawa (1999) observed that levels of spiramycine are quite high in the 
oviduct and suggests that this storage might be the reason for the longer 
presence of spiramycine in egg white than in yolk (Yoshida et al., 1971; 
Roudaut and Moretain, 1990). He also found that levels of spiramycine, 
oxytetracycline and sulfamonomethoxine in albumen and oviduct tissue were 
higher than those in blood. 
The difference in distribution ratios between the ionophore type coccidiostats 
narasin and salinomycine is also striking. These two compounds differ only by 
one - uncharged - methyl group in a rather large and complicated molecule but 
evidently this difference is sufficient to result in a substantial difference in 
distribution (Table 1) between egg white and yolk. 
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1.7 Conclusions 
 
Drug residues will appear in both egg white and yolk after intentional or unintentional 
administration to laying hens. Bacitracine (Furusawa 2001) might be an exception to 
this rule. Intestinal absorption of the drug is a pre-requisite for residue formation, as 
transport via blood (plasma) is responsible for deposition of drugs in follicles on the 
ovary or in egg white in the oviduct. Physicochemical properties of the drugs and the 
physiology of the hen and physiology of egg formation will determine how much drug 
will be deposited and at what place. At present we cannot explain or predict from 
variables measurable in vitro what will happen in vivo. 
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1.8 Table 1: Literature data on drug residues in white and yolk  
 
Compound name pKa value Content in 
white in 
mg /kg  
Content in 
yolk in 
mg/kg 
Ratio 
white/yolk 
Exposure way Author 
Sulfonamides       
Sulfanilamide 10.5 35 43 0.8 1000 mg/l in water 8 days Blom (1975) 
Sulfadiazine   6.5 0.22 0.14 1.6 200 mg/l in water 5 days Atta et al. (2001) 
  0.32 0.18 1.8 400 mg/l in water 5 days Atta et al. (2001) 
  0.015 < 0.008 > 1.8 1.3 mg/kg in feed 21 days Tomassen et al. (1996b) 
  0.04 < 0.008 > 5 3.8 mg/kg in feed 21 days Tomassen et al. (1996b) 
  0.10 0.022 4.5 8.1 mg/kg in feed 21 days Tomassen et al. (1996b) 
Sulfadimethoxine    6.3 4.6 1.7 2.7 400 mg/kg feed 5 days Furusawa et al. (1994) 
  8.2 1.6 5 500 mg/kg feed 14 days Furusawa (2001) 
  3.0 1.5 2 0.02 % in rofenaid feed C 14, 14 days Laurencot et al. (1972) 
  0.15 0.05 3 25 mg/kg in feed 21 days Nagata et al. (1989) 
  0.25 0.1 2.5 50 mg/kg in feed 21 days Nagata et al. (1989) 
  0.5 0.2 2.5 100 mg/kg in feed 21 days Nagata et al. (1989) 
  0.04 0.02 2 10 mg/kg in feed 14 days Nagata et al. (1992) 
  0.04 0.01 4 10 mg/kg in feed  14 days Nagata et al. (1992) 
  35 12 2.9 2000 mg/kg in feed 25 days Onodera et al. (1970) 
  35 9 3.9 500 mg/l in water 5 days Roudaut (1993) 
       
       
       
         21 
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Compound name pKa value Content in 
white in 
mg /kg  
Content in 
yolk in 
mg/kg 
Ratio 
white/yolk 
Exposure way Author 
Sulfadimidine 7.5 56 45 1.2 1000 mg/l in water 8 days Blom (1975) 
  97 83 1.2 2000 mg/l in water 8 days Blom (1975) 
  20 5 4 5 x 100 mg/kg BW in 5 days Geertsma et al. (1987) 
  19 19 10 500 mg/kg feed 14 days Furusawa (2001) 
  70 30 2.3 1000 mg/l in water 5 days Krieg (1966) 
  51 34 1.5 1000 mg/l in water 5 days Roudaut (1993) 
  50 34 1.5 1000 mg/l in water 5 days Roudaut and Garnier (2002) 
  70 45 1.6 2000 mg/l in water 5 days Roudaut and Garnier (2002) 
  38 23 1.7 1500  mg/kg in feed 5 days Seib (1991) 
Sulfamerazine 7.0 23 6 3.8 2000 mg/kg in feed 25 days Onodera et al. (1970) 
Sulfamethoxazole  20 1.8 11 2000 mg/kg in feed 5 days Oikawa et al. (1977) 
  39 2.9 14 4000 mg/kg in feed 5 days Oikawa et al. (1977) 
Sulfamonomethoxine    6.0 6.8 1.5 4.5 400 mg/kg in feed 5 days Furusawa and Mukai (1995) 
  5.2 1.1 4.9 400 mg/kg in feed 7 days Furusawa (1999) 
  10.5 2.8 3.8 500 mg/kg feed 14 days Furusawa (2001) 
  0.20 0.04 5 25 mg/kg in feed 21 days Nagata et al. (1989) 
  0.35 0.07 5 50 mg/kg in feed 21 days Nagata et al. (1989) 
  1.0 0.2 5 100 mg/kg in feed 21 days Nagata et al. (1989) 
  21 5 4 2000 mg/kg in feed 25 days Onodera et al. (1970) 
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Compound name pKa value Content in 
white in 
mg /kg  
Content in 
yolk in 
mg/kg 
Ratio 
white/yolk 
Exposure way Author 
       
Sulfaquinoxaline 5.5 50 36 1.4 400 mg/l in water 8 days Blom (1975) 
  2.3 2.0 1.2 200 mg/kg in feed 7 days Furusawa et al. (1998) 
  0.95 1.6 0.6 60 mg/kg in feed 14 days Nose et al. (1982) 
  3.7 1.4 2.6 100 mg/kg in feed 7 days Petz (1993) 
  80 20 4 350 mg/l water 3 days Rana et al. (1993) 
  3.4 2.9 1.2 500 mg/kg in feed 12 days (intermittent) Righter et al. (1970) 
  8 2 4 400 mg/l water 3 days Romvary and Simon (1992) 
  8.3 2 4.2 6000 mg/l in water Sakano et al. (1981) 
Folic acid antagonists       
Ormetoprim  0.44 5.5 0.08 500 mg/kg feed 14 days Furusawa (2001) 
  0.25 3.5 0.07 0.02 % in feed C14, 14 days Laurencot et al. (1972) 
Trimethoprim   6.6 0.24 0.43 0.6 200 mg/l in water 5 days Atta et al. (2001) 
  0.43 0.8 0.5 400 mg/l in water 5 days Atta et al. (2001 
  <0.02 0.05 < 0.4 4 mg/kg in feed 19 days Nagata et al. (1991) 
  0.02 0.25 0.08 16 mg/kg in feed 19 days Nagata et al. (1991) 
  0.07 0.9 0.08 56 mg/kg in feed 19 days Nagata et al. (1991) 
Pyrimethamine 7.0 2 88 0.02 100 mg/l in water 8 days Blom (1975) 
  <0.01 0.03 < 0.3 0.1 mg/kg in feed 21 days Nagata et al. (1990) 
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Compound name pKa value Content in 
white in 
mg /kg  
Content in 
yolk in 
mg/kg 
Ratio 
white/yolk 
Exposure way Author 
  0.04 0.7 0.06 1 mg/kg in feed 21 days Nagata et al. (1990) 
  0.13 3.3 0.04 10 mg/kg in feed 21 days Nagata et al. (1990) 
  <0.02 0.25 < 0.08 1 mg/kg in feed 14 days Nagata et al. (1992) 
Coccidiostats       
Amprolium  0.4 5 0.08 500 mg/kg feed 14 days Furusawa (2001) 
  0.006 0.2 0.03 5 mg/kg in feed 10 days Kan et al. (1989) 
  0.05 1.7 0.03 250 mg/kg in feed 10 days Kan et al. (1989) 
  0.05 0.6 0.08 100 mg/kg in feed 14 days Nose et al. (1982) 
Decoquinate  0.02 0.6 0.03 40 mg/kg in feed 14 days Nose et al. (1982) 
Dinitolmide  0.15 1.6 0.09 125 mg/kg in feed 14 days Nose et al. (1982) 
Meticlorpindol  5 2.5 2 110 mg/kg in feed 10 days Mattern et al. (1990) 
Nicarbazine  0.3 13 0.02 500 mg/kg feed 14 days Furusawa (2001) 
Other feed additives       
Dimetridazole  0.002 0.002 1 0.95 mg/kg in feed 21 days Kan et al. (1995) 
  0.01 0.01 1 4.7 mg/kg in feed 21 days Kan et al. (1995) 
  0.25 0.30 0.8 3 x 50 mg/kg BW 3 days Posyniak et al. (1996) 
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Compound name pKa value Content in 
white in 
mg /kg  
Content in 
yolk in 
mg/kg 
Ratio 
white/yolk 
Exposure way Author 
  1.2 1.4 0.9 3 x 250 mg/kg BW 3 days Posyniak et al. (1996) 
Olaquindox  0.002 <0.001 > 2 0.39 mg/kg in feed 21 days Keukens et al. (1996) 
  0.007 0.003 2.3 1.7 mg/kg in feed 21 days Keukens et al. (1996) 
  0.02 0.008 2.5 5.4 mg/kg in feed 21 days Keukens et al. (1996) 
Tetracyclines       
Chlortetracycline   3.4; 7.4;
9.3 
0.1 0.4 0.25 600 mg/kg in feed 5 days Roudaut et al. (1989) 
  0.25 0.25 1 8000 mg/kg in feed 7 days Yoshida et al. (1973a) 
Doxycycline  3.5; 7.7;
9,5 
 0.015 <0.01 > 1.5 1.1 mg/kg in feed 21 days  Tomassen et al. (1996a) 
  0.08 0.04 2 6.7 mg/kg in feed 21 days Tomassen et al. (1996a) 
  0.15 0.07 2 11.5 mg/kg in feed 21 days Tomassen et al. (1996a) 
  11 3.5 3 0.5 g/l water 7 days Yoshimura et al. (1991) 
Minocycline  2.8; 5.0;
7.8; 9.5 
 0.7 0.1 7 90 mg/l water 4 days Kan and Rump unpublished results 
(1989) 
Oxytetracycline   3.3; 7.3;
9.1 
0.10 0.06 1.6 400 mg/kg in feed 7 days Furusawa (1999) 
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Compound name pKa value Content in 
white in 
mg /kg  
Content in 
yolk in 
mg/kg 
Ratio 
white/yolk 
Exposure way Author 
  0.21 0.25 0.8 500 mg/kg feed 14 days Furusawa (2001) 
  1.9 2.9 0.7 2 g/l water 7 days Nagy et al. (1997) 
  <0.05 0.2 < 0.2 400 mg/l 7 days Omija et al. (1994) 
  0.05 0.5 0.1 600 mg/l 7 days Omija et al. (1994) 
  0.25 0.6 0.4 800 mg/l 7 days Omija et al. (1994) 
  0.13 0.3 0.4 0.25 g/l water 5 days Roudaut et al. (1987a) 
  0.15 0.3 0.5 0.5 g /l  water 5 days Roudaut et al. (1987a) 
  0.08 <0.20 > 0.4 300 mg/kg in feed 7 days Roudaut et al. (1987a) 
  0.17 0.5 0.3 600 mg/kg in feed 7 days Roudaut et al. (1987a) 
  0.6 0.5 1.2 2000  mg/kg in feed 7 days Yoshida et al. (1973b) 
  0.8 1.1 0.7 4000  mg/kg in feed 7 days Yoshida et al. (1973b) 
  0.7 1.2 0.6 0.5 g/l  water 5 days Yoshimura et al. (1991) 
Tetracycline    8.3; 10.2 0.11 0.5 0.2 0.25 g/l water 5 days Roudaut et al. (1989) 
  0.2 0.9 0.2 0.5 g/l water 5 days Roudaut et al. (1989) 
  0.17 0.9 0.2 300 mg/kg in feed 7 days Roudaut et al. (1989) 
  0.3 1.5 0.2 600 mg/kg in feed 7 days Roudaut et al. (1989) 
Nitrofurans       
Furazolidone  0.05 0.07 0.7 100 mg/kg in feed 28 days Botsoglou et al. ( (1989) 
  0.1 0.15 0.7 200 mg/kg in feed 14 days Botsoglou et al. ( (1989) 
  0.2 0.25 0.8 400 mg/kg in feed 14 days Botsoglou et al. ( (1989) 
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Compound name pKa value Content in 
white in 
mg /kg  
Content in 
yolk in 
mg/kg 
Ratio 
white/yolk 
Exposure way Author 
  0.22 0.37 0.6 500 mg/kg feed 14 days Furusawa (2001) 
  0.015 0.010 1.5 400 mg/kg in feed 7 days Krieg (1972) 
  0.48 0.17 2.8 400 mg/kg in feed 8 days McCracken et al. (2001) 
  0.4 0.5 0.8 400 mg/kg in feed 14 days Petz (1984) 
Furaltadon  0.1 0.2 0.5 100 mg/kg in feed 7 days Petz (1993) 
Nitrofurazone    9.28 0.25 0.4 0.6 100 mg/kg in feed 7 days Petz (1993) 
Nitrofurantoine    7.2 0.1 <0.001 > 100 100 mg/kg in feed 7 days Petz (1993) 
Quinolones       
Flumequine 6.25 2.1 0.3 7 90 mg/l water 10 days van Leeuwen and van Gend (1989) 
  9 1.7 5.3 200 mg/l water 5 days Riberzani et al. (1993) 
  2 0.3 6.7 5 x 12 mg/kg BW 5 days oral Samaha et al. (1991) 
Oxolinic acid 6.3 1.5 0.2 7.5 0.15  (0.5??) g/l water 5 days Roudaut and Boisseau (1990) 
  11.5 1.2 9.6 300 mg/kg in feed 5 days Roudaut (1998) 
Enrofloxacine    6.2 1.1 0.3 3.7 5 mg/kg/day in water 5 days Gorla et al. (1997) 
Ciprofloxacine 6.3 < 0.15 0.18 < 0.8 5 mg/kg/day in water 5 days Gorla et al. (1997) 
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Compound name pKa value Content in 
white in 
mg /kg  
Content in 
yolk in 
mg/kg 
Ratio 
white/yolk 
Exposure way Author 
       
Macrolides       
Erythromycine 8.7 0.04 IU/g 0.12 IU/g 0.3 0.22 g/l water 5 days Roudaut and Moretain (1990) 
  0.1 IU/g 0.3 IU/g 0.3 0.5 g/l water 5 days Roudaut and Moretain (1990) 
  0.03 IU/g 0.12 IU/g 0.3 400 mg/kg in feed 7 days Roudaut and Moretain (1990) 
  0.47 1.54 0.3 0.5 g/l water 7 days Yoshimura et al. (1978) 
Kitasamycine   6.7 0.35 0.27 1.3 0.5 g/l water 7 days Yoshimura et al. (1978) 
Oleandomycine  4.6 11.4 0.4 0.5 g/l water 7 days Yoshimura et al. (1978) 
Spiramycine   8.0 0.40 0.32 1.3 400 mg/kg in feed 7 days Furusawa (1999) 
  2.1 IU/g 4.5 IU/g 0.5 0.4 g/l water 5 days  Roudaut and Moretain (1990) 
  0.9 IU/g 1.3 IU/g 0.7 400 mg/kg in feed 7 days  Roudaut and Moretain (1990) 
  3 2.2 1.4 1000 mg/kg in feed 7 days Yoshida et al. (1971) 
  2.7 4.2 0.6 0.5 g/l water 7 days Yoshimura et al. (1978) 
Tylosin 7.1 0.05 0.05 1 500 mg/kg feed 14 days Furusawa (2001) 
  0. 25  IU/g 0.6 IU/g 0.4 1 g/l water 5 days Roudaut and Moretain (1990) 
  5 5 1 8000 mg/kg in feed 7 days Yoshida et al. (1973c) 
  1 1 1 0.5 g/l water 7 days Yoshimura et al. (1978) 
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Compound name pKa value Content in 
white in 
mg /kg  
Content in 
yolk in 
mg/kg 
Ratio 
white/yolk 
Exposure way Author 
Ionophores       
Monensin  0.1 0.08 1.3 110 mg/kg in feed 7 days Keukens, Aerts and Kan unpublished 
results (1987) 
Narasin  0.25 0.8 0.3 70 mg/kg in feed 7 days Keukens, Aerts and Kan unpublished 
results (1987) 
Salinomycine  < 0.01 1.4 < 0.007 30 mg/kg in feed 14 days Akhtar et al. (1996) 
  0.08 2 0.04 60 mg/kg in feed 14 days Akhtar et al. (1996) 
  0.1 2.8 0.04 90 mg/kg in feed 14 days Akhtar et al. (1996) 
  0.2 3.7 0.05 150 mg/kg in feed 14 days Akhtar et al. (1996) 
  0.05 1.5 0.03 60 mg/kg in feed 7 days Keukens, Aerts and Kan unpublished 
results (1987) 
  <0.01 0.22 < 0.05 66 mg/kg in feed  days Sambeth et al. (1985) 
  <0.01 0.4 < 0.02 60 mg/kg in feed 5 days Sinigoj-Gacnik (1996) 
Anthelmintics       
Flubendazole  <0.02 0.04 < 0.5 2.6 mg/kg in feed 21 days Kan et al. (1998) 
  0.02 0.1 0.2 9.4 mg/kg in feed 21 days Kan et al. (1998) 
  0.03 0.3 0.1 27.0 mg/kg in feed 21 days Kan et al. (1998) 
Ivermectine  <0.0005 0.001 < 0.5 0.11 mg/kg in feed 21 days Van Dijk et al. (1997) 
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Compound name pKa value Content in 
white in 
mg /kg  
Content in 
yolk in 
mg/kg 
Ratio 
white/yolk 
Exposure way Author 
  <0.0005 0.005 < 0.1 0.36 mg/kg in feed 21 days Van Dijk et al. (1997) 
  <0.0005 0.02 < 0.02 0.76 mg/kg in feed 21 days Van Dijk et al. (1997) 
Various       
Ampicilline 2.5; 7.3 0.008 0.025 0.3 1.5 g/l water 5 days Roudaut et al. (1987b) 
Chloramphenicol 5.5 2 10 0.2 400 mg/l water 10 days Arnold and Somogyi (1986) 
  0.35 2 0.17 500 mg/kg feed 14 days Furusawa (2001) 
  0.5 1.8 0.3 400 mg/kg in feed 14 days Petz (1984) 
  0.05 0.2 0.3 200 mg/kg in feed 5 days Samouris et al. (1998) 
  0.5 1.5 0.3 500 mg/kg in feed 5 days Samouris et al. (1998) 
  0.5 2.5 0.2 800 mg/kg in feed 5 days Samouris et al. (1998) 
  1.2 4 0.3 1000 mg/kg in feed 5 days Samouris et al. (1998) 
  0.15 0.2 0.8 40 mg/l water 5 days Sisodia and Dunlop (1972) 
Kanamycine 7.2 < 0.5 1.5 < 0.3 4.000 mg/kg feed 7 days Yoshida et al. (1976) 
  <0.5 2.2 < 0.2 8.000 mg/kg feed 7 days Yoshida et al. (1976) 
  <0.5 4 < 0.1 16.000 mg/kg feed 7 days Yoshida et al. (1976) 
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2 EXPERIMENTAL PART 
 
2.1 Introduction 
 
The available data from the literature - with the exception of the work of Blom (1975) 
 lack a comparative approach, that should help to elucidate what physicochemical 
factors determine the partitioning of drugs between egg white and yolk. 
The following factors were considered of possible importance: 
• Lipid solubility 
• Distribution between the aqueous and organic phase (log p value) 
• pKa value 
• Protein binding  
 
Therefore we ran a number of tests with a group of sulfonamides, as a possible 
relationship between physicochemical characteristics and distribution within the egg 
was considered more likely to be found within a group of related compounds. A 
further advantage of choosing sulfonamides as model substances was their relative 
stability in different matrices and easiness to carry out residue determinations. The 
different sulfonamides and their structural formulas are given in Figure 10. 
 
The following experiments were therefore planned: 
 
1. Determination of log p values of 11 sulfonamides (Figure 10), with pKa values 
ranging from 4.7  11.3, with both dichloromethane and cyclohexane as organic 
phase against phosphate buffers of pH 6.0 and 7.6 respectively. The pH of yolk is 
around 6.0 when the egg is just laid and that of egg white at that time is 7.6.  
2. Administration of feeds with the 11 different sulfonamides to groups of 3 laying 
hens during 3 weeks and assessment of the residues in mixed samples per group 
of both yolk and egg white after about 2 weeks of administration. 
3. Administration of feeds with 5 sulfonamides, diverging in physicochemical 
characteristics, to groups of 5 laying hens during 3 weeks. Assessment of the 
residues in mixed samples per hen of both yolk and egg white and the amount of 
protein or macromolecular binding in vivo in both matrices. 
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Basic sulfonamide structure
NH= SO2 NH2R
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Figure 10: Structural formulas of the sulfonamides examined 
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2.2 Materials and methods 
 
2.2.1 Determination of partitioning coefficients 
The OECD guideline 107 was used as starting point for the determination of the 
partitioning coefficients. They lead to the following requirements for the testing: 
1. Testing of one substance (as pure as possible) at the time with a not too high 
concentration. 
2. The substance must be water soluble and stable in aqueous solutions; the 
substances must not associate or dissociate or behave as a surfactant. 
3. Three different concentrations of the substance or of the aqueous/organic phase 
should be tested in duplicate and the equilibrium should be reached at one 
constant temperature and pressure. 
 
The partitioning coefficients were determined at both pH 6.0 (to mimic yolk pH) and 
7.6 (to mimic egg white pH) of the aqueous phase and dichloromethane and 
cyclohexane as the organic phase. Octanol, which is often used in these kinds of 
measurements, was avoided, as the formation of hydrogen bonds between solvent 
and sulfonamides, which could lead to aberrant values, was feared. 
The sulfonamide buffer solutions should have had an strength of 0.3-0.4 mM, but this 
could not always be achieved due to the limited solubility of the sulfonamides in 
aqueous media. The solutions were prepared in a phosphate buffer saturated with 
dichloromethane. 
 
The partitioning between the aqueous and the organic phase was carried out in 25 ml 
glass tubes with a screwing cap lined with teflon®. The tubes were rotated at 
approximately 20 rpm during some 30 minutes. The tubes were then centrifuged at 
approximately 1000 g for 15 minutes and afterwards left for equilibration for about 
one hour. All processes took place at room temperature being about 23 0C. 
To achieve three different concentrations of the substance as prescribed by the 
above mentioned OECD guideline, amounts of 18, 12 and 6 ml aqueous buffer were 
mixed with 6, 12 and 18 ml of the organic phase. The sparely water-soluble 
sulfonamides sulfachloropyrazine, sulfaquinoxaline and sulfadimethoxine were mixed 
in the ratios 21, 22 and 23 ml aqueous buffer and 3, 2 and 1 ml organic phase. 
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2.3 Analysis of sulfonamides 
 
The HPLC analysis of sulfonamide concentrations in the different samples was 
carried out on a C 18 column with an ammonium acetate buffer/acetonitrile mixture 
as eluent and UV/fluorescence detection as outlined below. 
 
2.3.1 Sulfonamide standards 
Sulfisoxazole; Sigma nr. S 6377 
Sulfachloropyrazine-sodium.1 aq; Ciba-Geigy prod.standard. 90   
Sulfaquinoxaline-sodium; Sigma nr. S 7382 
Sulfamethoxazole; Sigma nr. S 7507 
Sulfadimethoxine; Sigma nr. S 7007 
Sulfadiazine; Sigma nr. S 8626 
Sulfamerazine; Sigma nr. S 8867 
Sulfadimidine; Sigma nr. S 6256 
Sulfapyridine; Sigma nr. S 6252 
Sulfanilamide; Sigma nr. S 9251 
Sulfaguanidine; Sigma nr. S 8751 
 
2.3.2 Chemicals 
Acetonitrile p.a.; Merck nr. 3 
Ammoniumacetate p.a.; Merck nr 1116 
Acetic acid 99-100% p.a.; Baker nr. 6052 
Buffer pH 7.00; Merck nr. 9477 
Buffer pH 4.00; Merck nr. 9475 
Citric acid monohydrate p.a.; Merck nr. 244 
Dichloromethane UVASOL; Merck nr. 6048 
Ethylacetate UVASOL; Merck nr.863 
Methanol p.a.; Merck nr. 6009 
Ortho-phosphoric acid 85 % p.a.; Merck nr. 573 
Petroleum-ether boiling point 40-60 oC p.a.; Merck nr. 1775 
di-Potassiumhydrogenphosphate (anhydrous) p.a.; Merck nr 5104 
Sodiumdihydrogenphosphate monohydrate p.a.; Merck nr. 6346 
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di-Sodiumhydrogenphosphate dihydrate p.a.; Merck nr 6580 
Sodiumhydroxide pellets p.a.; Merck nr. 6498 
Water (milliQ) 
 
2.3.3 Solutions 
Ammoniumacetate buffer 0.01 M pH 5.3 
Dissolve 0.77 g ammoniumacetate in ca. 800 ml water. Adjust to pH 5.3 with 
approximately 10 drops 100 % acetic acid measured with a pH meter. Adjust volume 
to1000 ml with water and mix well. 
 
Dichloromethane saturated with sodiumphosphatebuffer 0.10 M pH 6.0 and pH 7.6 
Transfer approximately 800 ml dichloromethane into a bottle with screw cap and teflon 
lining. Add approximately 100 ml sodium phosphate buffer 0.10 M pH 6.0 or pH 7.6 and 
close the bottle. Mix during 24 hours on a mechanical shaker at room temperature and 
let the phases separate for 24 hours at 23 0C. Take the lower layer by pipette. During 
transfer of the pipette through the upper layer apply some air pressure on it, in order to 
avoid the upper layer from entering the pipette. 
 
Phosphate buffer 0.05 M pH 10 
Dissolve 4.36 g di-potassiumhydrogenphosphate in approximately 400 ml water. Adjust 
pH to10.0 with approximately 13 drops of 1 M sodiumhydroxide measured with a pH 
meter. Adjust the volume to 500 ml with water and mix well. 
 
Ortho-phosphoric acid 0.5 M 
Add 3.4 ml ortho-phosphoric acid 85 % to approximately 50 ml water. Add water till 100 
ml and mix well. 
 
Sodiumcitratebuffer 2 M pH 4.2 
Dissolve 21 g citric acid monohydrate with approximately 25 ml water and 
approximately 10 ml 10 M sodiumhydroxide. Adjust pH to 4.2 with a pH meter by 
adding approximately 5 ml 10 M sodiumhydroxide; make sure that the solution is at 
room temperature. Add water till a volume of 50 ml and mix well. 
 
 35
Chapter 2 
Sodium-di-hydrogenphosphate solution 0.10 M 
Take 13.8 g sodium-di-hydrogenphosphate monohydrate. Dissolve and adjust the 
volume with water till 1000 ml and mix well. 
 
di-Sodiumhydrogenphosphate solution 0.10 M 
Take 8.8 g di-sodiumhydrogenphosphate dihydrate. Dissolve and adjust the volume 
with water till 1000 ml and mix well. 
 
Sodiumphosphatebuffer 0.10 M pH 6.0 and pH 7.6 
Mix the sodium-di-hydrogenphosphate solution 0.10 M and the di-
sodiumhydrogenphosphate solution 0.10 M till the desired end-pH is obtained, by 
measuring with a calibrated pH-meter. To obtain pH 6.0 or pH 7.6 respectively the 
mixing ratios will be approximately 85:15 and 15:85. Mix and measure pH after each 
addition and add smaller amounts when the pH reaches it desired value. 
 
Sodiumphosphatebuffer 0.10 M pH 6.0 and pH 7.6 saturated with dichloromethane 
Transfer approximately 800 ml sodiumphosphatebuffer 0.10 M pH 6.0 or pH 7.6 into a 
bottle with screw cap lined with teflon. Add approximately 100 ml dichloromethane and 
close the bottle. Mix during 24 hours on a mechanical shaker at room temperature and 
let the phases separate for 24 hours at 23 0 C. Use the upper layer. 
 
Sodiumphosphatebuffer approximately 0.01 M and pH 7.6 
Dilute sodiumphosphatebuffer 0.10 M pH 7.6 in a ratio1:10 with water. 
 
Sodiumhydroxide 10 M 
Dissolve 40 g sodiumhydroxide pellets in 100 ml water. 
 
Sodiumhydroxide 1 M 
Dilute10 ml 10 M sodiumhydroxide with water until 100 ml and mix well. 
 
Sulfonamide spike-solutions 
Accurately weigh about 2.5 mg sulfonamide in a 100 ml bottle. Dissolve it in 
sodiumphosphatebuffer ca. 0.01 M and about pH 7.6 . Add water till 100 ml and mix 
well. 
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2.3.4 Apparatus 
A/D Converter 18652A ; Hewlett-Packard 
Analytical Systems 3359AX (HP 1000); Hewlett-Packard 
Balance (0.01 mg accuracy), AT 250; Mettler 
Centrifuge, IECCR-6000; IEC 
Desiccator; glass  
Dispenser, Multipette; Eppendorf 
Evaporator, Reacti-vap&therm ; Pierce 
Fluorescence HPLC Monitor RF-530 ; Shimadzu 
Guard Column bestelnr.28141, 1 cm length 2 mm ID stainless steel column packed with 
Reversed Phase R2; Chrompack 
Horizontal mechanical mixer; Edmund Bühler 
HPLC Column Chromsep ordernr. 28267 2*10 cm length 3 mm ID glass column packed 
with Chromspher C18, 5 µm; Chrompack 
Liquid Chromatograph + LC Terminal, Series 4 ; Perkin-Elmer 
Membrane pump Divac 2.4L; Leybolt 
pH meter (2 decimals accuracy), SA 720; Orion 
Pipettes fixed volume 10 µl-1 ml; Eppendorf 
Programmable Multiwavelength Detector Type 490 ; Waters 
Recorder BD 111/112 ; Kipp & Zonen 
Rotation apparatus for 24 tubes; GFL 3025  
Sample Injector Model 230 + 401 Dilutor + 20µl loop; Gilson 
Tube shaker, Vortex-Evaporator; Buchler 
Ultrasonic bath, T 480/H-2; ELMA 
Ultra-turrax T25; IKA 
Vial-crimper for 12 mm cap's; Phase Sep 
 
2.3.5 Usables 
Glass round bottom tubes 15 ml 16*100 mm; Renes 
Glass culture tubes with screwing caps and teflon® lining 25 ml, 18*145 mm; Elgebe 
Glass flask with screwing cap and teflon® lining 
Pasteur pipette (glass) 23 cm long 
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Polypropylene pointed tube with screwing cap 50 ml nr. 227261; Greiner 
Polypropylene round bottom tube 
Sep-Pak Silica Plus column nr 20520; Waters  
Nitrogen gas, purity 2.8 or better 
Vial (glass) 1-2 ml 12*32 mm with crimp-cap; Phase Sep 
Disposable syringe 50 ml, Plastipak; Becton Dickinson 
 
2.3.6 Sample preparation 
Aqueous samples 
The dilution of the sample with 1.00 ml eluent is aimed at reaching a concentration of 
about 2 µg/ml sulfonamide in the vial.  
 
Samples from the organic phase 
Transfer sample into polypropylene tube and transfer from here the required amount 
into a vial. Evaporate under nitrogen and dissolve the residue in 0.250 ml acetonitrile; 
Add 1.00 ml 0.01 M ammoniumacetate buffer pH 5.2 (1.5 % volume contraction). 
Sulfaguanidine had such a low partitioning coefficient, that a larger amount of 
dichloromethane had to be evaporated first. 
  
Yolk/Egg white 
Pure yolk or white is homogenised with an ultra-turrax (30 seconds at about 10.000 
rpm) and 5.0  0.05 g is weighed into a 50 ml polypropylene pointed tube. Add 0.5 ml of 
a 2 M sodium citrate buffer pH 4.2 and mix immediately; add then 40 ± 0.5 ml 
dichloromethane and mix shortly at once. Let the air escape and shake the tube 
horizontally for 30 minutes at 200 rpm. 
Yolk samples, centrifuge for 5 minutes at about 1000 g. White samples, break the gel 
by shaking. 
Penetrate the clean lower surface of the tube with a sharp needle and collect the extract 
in a 100 ml Erlenmeyer; Yolk samples will yield 38 ± 0.5 ml extract and egg white 
samples 33 ± 2 ml. 
Connect the "barrel" of a 50 ml disposable syringe to a Sep-Pak Silica Plus column 
(stored in a desiccator) and fill the "barrel" with 10.0 ml petroleum-ether 40-60 first and 
with 10.0 ml extract thereafter. Suck the fluid at a 10-20 ml/min rate through the column, 
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rinse with 5 ml 1:1 petroleum-ether 40-60/dichloromethane and dry at least 20 minutes 
with 100 ml/min nitrogen gas. 
If no further concentration is needed (content > 0.25 µg/g): elute with 5.0 ml 0.05 M 
phosphate buffer pH 10 at a rate of about 10 ml/minute. Weigh the collected amount 
(approximately 4 ml) together with the glass tube and adjust the pH of the eluate to 5.5-
4.0 with 250 µl 0.5 M ortho-phosphoric acid. Transfer an aliquot part to a 11 x 32 mm 
vial for HPLC analysis. 
Concentration can be achieved by collecting the eluate, adjusting pH to 6.0-5.5 with 200 
µl 0.5 M ortho-phosphoric acid and shake 5 minutes with 5 ml ethylacetate. Centrifuge 5 
minutes at approximately 1000 g, transfer as much ethylacetate as possible to a glass 
tube and extract the aqueous phase again with 5 ml ethylacetate. Evaporate the 
combined extracts under nitrogen gas at about 40 oC. The residue is dissolved in 20 µl 
acetonitrile and 500 µl 0.01 M ammonium acetate buffer pH 5.3 is added. After an 
ultrasonic treatment during 10 minutes the solution is transferred for the HPLC analysis 
into a 11 x 32 mm vial. 
 
2.3.7 Recovery measurements 
Linearity of the clean-up method has not been checked. Therefore recovery 
measurements were made at expected concentrations in the samples. 
Blank eggs were treated in the same way as residue-containing eggs. After weighing 
the required amount into a 50 ml polypropylene tube, 20 µl of the spike solution of 
sulfisoxazole, sulfadiazine, sulfamerazine, sulfadimidine and sulfapyridine was added to 
the yolk to obtain a spike level of 100 ppb to measure recovery. All other recovery 
measurements in yolk and those in white were done at 500 ppb after a spike of 100 µl. 
Then the samples were homogenised with the aid of a Vortex mixer and they were 
incubated for 1.5 hours at room temperature. Then citrate buffer was added and the 
clean-up proceeded as described above for yolk and egg white samples. 
At the same time duplicate 100 µl portions of the spike solutions were pipetted into the 
vials and after addition of 1.25 ml eluent these samples were analysed by HPLC to 
determine the real concentration. 
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2.3.8 HPLC-conditions 
Isocratic 
Eluent: 78% 0.01 M ammoniumacetate pH 5.2 + 22% acetonitrile  
 
Gradient 
Starting eluent: 0.01 M ammoniumacetate buffer pH 5.3 with 2.5 % acetonitrile 
Final eluent: 0.01 M ammoniumacetate buffer pH 5.3 with 22 % acetonitrile 
Equilibrate during 20 minutes with 100 % starting eluent, then injection, then in 1 minute 
linear to 100 % final eluent. Elute during 15 minutes with final eluent and finally switch 
back to starting eluent. 
  
Dwell volume of pump + pulse equaliser: 3.5 ml 
Flow: 0.6 ml/min  
Pressure: ca. 10 Mpa 
Column temperature: ca. 26 °C 
Solvent for injection in isocratic run: eluent 
Solvent for injection meant for gradient elution: ca 0.05 M phosphate buffer with pH 
lower or equal to pH (if no concentration was needed) or starting eluent (if concentration 
was carried out) 
Injection: 100 µl sample in 20 µl loop 
 
UV-detector: Channel  1  2  3  4 
   Mode  A  A  A  A 
   AUFS  1.000  0.100  1.000  0.100 
   Wavelength 280 nm 280 nm 254 nm 254 nm 
   Second List Yes  Yes  Yes  Yes 
   Time Const.  1.0  1.0  1.0  1.0 
   Threshold  0% FS 0% FS 0% FS 0% FS 
   Auto Zero  Yes  Yes  Yes  Yes 
   Chart Mark No  Yes  No  Yes 
   Auto Range No  No  No  No 
   Polarity  +  +  +  + 
   Chart Zero 0% FS 0% FS 0% FS 0% FS 
   Connected to A/D 4  Rec.blue  A/D_1  
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Fluorescence detector: Excitation  275 nm 
     Emission  340 nm 
     Sensitivity  High 
     Range  16 
     Connected to A/D_7 and Recorder red 
 
Recorder: Chart speed 5 mm/min. 
 
Data acquisition and management: Data acquisition lasted 20 minutes. When running 
the gradient programme it thus extends into the equilibration phase. On applying the 
gradient conditions a chromatogram with the following peaks and retention times was 
obtained: 
 
Name      Approximate retention time in minutes 
Dead volume (potassium nitrate)    1.1 
Sulfaguanidine       3.3 
Sulfanilamide        3.9 
Sulfadiazine        8.8 
Sulfapyridine        9.8 
Sulfamerazine      10.1 
Sulfisoxazole       10.6 
Sulfadimidine       11.1 
Sulfachloropyrazine     12.8 
Sulfamethoxazole     13.1 
Sulfaquinoxaline     17.2 
Sulfadimethoxine     18.0 
 
2.3.9 Ultrafiltration 
Two ml egg white or yolk was transferred into a disposable ultrafiltration cartridge 
(Ultrafree-CL Polysulfone 30000 NWML, Millipore Cat.No. UFC4TTK25) and 
centrifuged for 2 hours at 3000 rpm (1000 g) in a Sorvall RC-5B centrifuge with SA-600 
rotor. The sample size of the ultrafiltrate for HPLC was 0.3 ml. 
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2.4 Animal experiments 
 
Trial 1: 
Groups of 3 laying hens received during 3 weeks feeds with the following amounts of 
sulfonamides added (Table 2) 
 
Table 2: Concentrations in the feed 
Group  Sulfonamide mg/kg feed 
1: Sulfisoxazole 100 
2: Sulfachloropyrazine 50 
3: Sulfaquinoxaline 20 
4: Sulfamethoxazole 50 
5: Sulfadimethoxine 100 
6: Sulfadiazine 20 
7: Sulfamerazine 100 
8: Sulfadimidine 20 
9: Sulfapyridine 50 
10: Sulfanilamide 20 
11: Sulfaguanidine 100 
 
The eggs were stored at 4 0C until analysis and mixed samples per group of both 
yolk and egg white laid on days 14/15 and 16/17 have been analysed. 
 
Trial 2: 
Groups of five hens received during three weeks feed with 50 mg/kg of the following 
sulfonamides 
 
Group 1: Sulfachloropyrazine 
Group 2: Sulfadimethoxine 
Group 3: Sulfadiazine 
Group 4: Sulfadimidine 
Group 5: Sulfaguanidine 
 42
Chapter 2 
 
The eggs laid were stored at 4 0C until analysis. A mixed sample per animal of eggs 
laid from day 15-20 for both yolk and egg white was analysed. Protein binding was 
assessed by filtration through an ultrafiltration cartridge as described above. 
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2.5 Technical results  
 
2.5.1 Chemical analysis 
 
2.5.1.1 Chromatographic conditions 
The separation of the sulfonamides on the analytical column is influenced by many 
factors like pH, ionic strength and temperature of the column. Figure 11 illustrates the 
influence of pH on the separation.  
 
Figure 11: Influence of pH on separation of the sulfonamides (Top to bottom pH 
values of 3.00, 4.00, 4.90, 5.10, 5.14, 5.20 and 5.30) T = 26 0C, 0.01 M eluent 
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It is quite clear from these graphs that the optimal pH for separation of the different 
sulfonamides lies around pH 5.2-5.3. 
 
 
Figure 12: Influence of molarity on separation of the sulfonamides (Top to 
bottom molarity of 0.01, 0.02, 0.05 and 0.1 M) T = 26 0C, pH = 5.14 
 
Figure 12 shows the influence of molarity on the separation. Similarly Figure 13 
shows the influence of temperature. The different sulfonamides used in the laboratory 
and animal experiments were always tested one at the time. Therefore a method 
which always separated all eleven sulfonamides was not an absolute prerequisite. 
However for the sake of simplicity and avoidance of confusion, we have chosen to 
use the one set of conditions described above for all determinations in the study.  
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Figure 13: Influence of temperature on separation of the sulfonamides (Top to 
bottom temperature increase from 14 till 34 oC) pH = 5, 0.01 M eluent 
 
 
To illustrate the applicability of the conditions chosen, figures 14 and 15 show 
respectively a chromatogram of a blank sample to prove the absence of interfering 
peaks and a chromatogram after injection of a standard solution of  all eleven 
sulfonamides. 
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Figure 14: Chromatogram of blank egg white sample 
 
Figure 15: Chromatogram of standard sulfonamide solution 
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2.5.1.2 Linearity of the response 
The linearity of the detector response has also been tested and the figures included 
in the appendix prove that for all eleven sulfonamides a good linear response was 
obtained. 
 
2.5.1.3 Recovery percentages 
The recovery percentages from the aqueous and organic solutions were considered 
to be around 100 %, as no interfering factors are suspected to be present. 
The method used in this study to determine the sulfonamides in yolk and white was 
necessarily a compromise and for that reason some low recovery percentages 
occurred. In study 1 the following percentages were found: 
 
Recovery % Yolk White 
   
Sulfisoxazole 36 94 
Sulfachloropyrazine 81 86 
Sulfaquinoxaline 40 70 
Sulfamethoxazole 80 92 
Sulfadimethoxine 72 94 
Sulfadiazine 97 102 
Sulfamerazine 84 91 
Sulfadimidine 81 82 
Sulfapyridine 59 84 
Sulfanilamide 44 33 
Sulfaguanidine 20 < 3 
 
The low but consistent recovery percentages in some instances were nevertheless 
accepted as they were considered to have no impact on the outcome of the studies 
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2.5.2 Laboratory tests 
 
2.5.2.1 Partitioning coefficient  
The solubility of the sulfonamides in cyclohexane proved to be so low, that the 
measurements with this solvent have not been completed and the results are not 
shown here. 
The partitioning coefficients obtained with dichloromethane as the organic phase 
together with the Sd values are given in Table 3.  
The variability in the analytical results largely results from variation (about 5%) in the 
analyses in the dichloromethane layer. Evaporation of the solvent might have played an 
important role in causing this variability. The variability of the analyses of the aqueous 
layer was about 3 % and that of the standard solutions and the pipettes about 1 %.  
The reliability of the partitioning coefficients was tested according to the OECD 
guidelines, by comparison of the P value at any given condition to the average P 
value. This test did not show that a relationship between concentration and P values 
existed. The calculated log P values were well within the prescribed 0.3 log unit 
range, to be acceptable according to the guidelines. 
The partitioning of the sulfonamides between dichloromethane and an aqueous buffer 
solution showed large differences with sulfadimethoxine having (on average) the largest 
affinity for the organic phase and sulfaguanidine the least. The P and log P values  
which are also indicator of the solubility  showed no clear relationship with the pKa 
values of the different sulfonamides (see also figure 16).  
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Table 3: Sulfonamides with their pKa values and determined partitioning 
coefficients at pH 6.0 and 7.6 (Sd based on n=6) 
 Sulfonamide pKa P DCM/H2O  at pH 6.0 P DCM/H2O at pH 7.6 
  P Sd Log P P Sd Log P 
Sulfisoxazole 4.7 0.92 0.03 -0.037 0.0225 0.0010 -1.648 
Sulfachloropyrazine 5.1 4.17 0.18 0.619 0.114 0.003 -0.941 
Sulfaquinoxaline 5.5 47 6 1.67 2.16 0.13 0.33 
Sulfamethoxazole 5.9 4.7 0.3 0.67 0.190 0.026 -0.72 
Sulfadimethoxine 6.3 66 4 1.82 3.8 0.2 0.58 
Sulfadiazine 6.5 1.93 0.17 0.28 0.215 0.014 -0.67 
Sulfamerazine 7.0 5.1 0.6 0.70 1.228 0.018 0.089 
Sulfadimidine 7.5 9.4 0.8 0.97 5.5 0.2 0.738 
Sulfapyridine 8.4 2.68 0.14 0.43 2.49 0.11 0.40 
Sulfanilamide 10.5 0.092 0.002 -1.038 0.093 0.002 -1.030 
Sulfaguanidine 11.3 0.00183 0.00007 -2.738 0.00187 0.00006 -2.728 
 
4 6 8 10 12
pKa value
0.001
0.01
0.1
1
10
100
Pa
rti
tio
ni
ng
 c
oe
ffi
ci
en
t D
ic
hl
or
om
et
ha
ne
/w
at
er
Partitioning coefficient sulfonamides
pH = 6 pH = 7.6
 
Figure 16: Relationship between partitioning coefficient and pKa value of the 
sulfonamides 
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The partitioning at the different pH values of the aqueous buffer solutions did show  as 
anticipated - a relationship with the pKa values.  
 
Table 4 gives the calculated ratio of the measured partitioning ratios at pH values 6.0 
and 7.6 and the calculated distribution of the uncharged molecule over a semi-
permeable membrane separating two aqueous phases with pH values 6.0 and 7.6. This 
calculation was made according to Hogben et al. (1959). 
 
Table 4: Ratio of the partitioning coefficients measured at pH values 6.0 and 7.6 
and the calculated distribution.  
Sulfonamide pKa Ratio of P values measured 
at pH 6.0 and 7.6 
Calculated distribution at 
pH values 6.0 and 7.6 
Sulfisoxazole 4.7 40.9 38.0 
Sulfachloropyrazine 5.1 36.6 35.5 
Sulfaquinoxaline 5.5 21.8 30.5 
Sulfamethoxazole 5.9 24.7 22.6 
Sulfadimethoxine 6.3 17.4 14.0 
Sulfadiazine 6.5 9.0 10.3 
Sulfamerazine 7.0 4.2 4.5 
Sulfadimidine 7.5 1.7 2.2 
Sulfapyridine 8.4 1.08 1.15 
Sulfanilamide 10.5 0.99 1.00 
Sulfaguanidine 11.3 0.98 1.00 
 
The ratio of the partitioning at the pH values 6.0 and 7.6 showed a good correlation with 
the calculated distribution of the uncharged molecule over a semi-permeable 
membrane separating aqueous phases of these pH values. This strongly suggests that 
both the pKa values used in the calculations were about right and that in measuring the 
partitioning coefficients between organic and aqueous phases of different pH values, 
indeed only the uncharged molecules contribute to the distribution.  
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2.5.3 Animal trials 
 
2.5.3.1 Contents in yolk and egg white (Trial 1) 
The average contents in yolk and white measured in the samples after about two 
weeks of feeding (days 14/15 and 16/17) are given in Table 5. 
 
Table 5: Contents of the sulfonamides in feed, yolk and white.  
Sulfonamide Feed content 
mg/kg 
Yolk content in 
µg/kg* 
White content in 
µg/kg* 
Ratio white/yolk
Sulfisoxazole 100 10 + 32 SA < 15 
+ 16 SA 
< 1.5 
SA 0.48 
Sulfachloropyrazine 50 167 523 3.13 
Sulfaquinoxaline 20 261 542 2.08 
Sulfamethoxazole 50 117 418 3.56 
Sulfadimethoxine 100 370 860 2.32 
Sulfadiazine 20 15 135 9.27 
Sulfamerazine 100 26 226 8.77 
Sulfadimidine 20 9 27 2.88 
Sulfapyridine 50 < 4.5 
+ 31 SA 
< 100 
+ 16 SA 
? 
SA 0.51 
Sulfanilamide 20 137 149 1.09 
Sulfaguanidine 100 336 < 1000 ? (<3) 
*The yolk and white data are an average of two measurements in mixed samples; 
each mixed sample consisting of 5-6 individual egg samples and are corrected for 
recovery 
 
The recovery of the sulfonamides with high pKa values was quite low (see above), so 
the results of these compounds must be viewed with caution.  
The analyses of yolk and white from hens in the sulfisoxazole and the sulfapyridine 
groups indicated the possible presence of sulfanilamid. We have not been able to 
confirm these observations later on.  
 
The concentrations of the different sulfonamides are nearly always higher in egg white 
than in yolk. The ratio of the contents in white/yolk of the different sulfonamides does 
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not show a clear correlation with their pKa values (Table 3). The partitioning coefficients 
at the different pH values (Table 3) and the ratio of the partitioning coefficients at pH 
values 6.0 (Yolk) and 7.6 (White) given in Table 4 also showed no correlation with the 
observed white/yolk ratios. Figures 17 and 18 illustrate this. 
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Figure 17: The white/yolk ratio of 10 sulfonamides and the P values at pH 6 and 7.6 
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Figure 18: White/yolk ratio and ratio of p values at pH 6 and 7.6 of 10 sulfonamides  
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2.5.3.2 Contents in white and yolk (Trial 2) 
The residue levels reported in Table 6 are the results of a mixed sample of 4-5 eggs 
per animal laid during days 15-20 of the experiment. The results were corrected for 
recovery. 
 
The data show that at the same level in the feed (50 mg/kg) the different sulfonamides 
will give different residue levels in both yolk and white. They also show that although 
between hens there are considerable differences in absolute amounts, for each 
substance the ratio of the levels in white and yolk is quite constant.  
Furthermore the differences between substances both in absolute amounts and in the 
white/yolk ratio are also quite consistent. The ratios sometimes agree quite well 
between the two experiments and sometimes they do not. As the methodology was 
improved between both experiments (especially for sulfaguanidine) and levels near the 
detection limit (sulfadiazine, sulfadimidine and sulfaguanidine) were not present in the 
second trial, these factors may explain some of the differences in the results between 
the trials. 
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Table 6: Average contents of sulfonamides in yolk and egg  
Hen nr Sulfonamide Yolk in µg/kg White in µg/kg Ratio white/yolk 
1 Sulfachloropyrazine 191 416 2.17 
2 Sulfachloropyrazine 234 668 2.85 
3 Sulfachloropyrazine 253 705 2.79 
4 Sulfachloropyrazine 292 806 2.76 
5 Sulfachloropyrazine 401 1108 2.76 
Mean Sulfachloropyrazine 274 741 2.67 
6 Sulfadimethoxine 170 431 2.53 
7 Sulfadimethoxine 177 531 1.98 
8 Sulfadimethoxine 176 444 2.52 
9 Sulfadimethoxine 161 330 2.05 
10 Sulfadimethoxine 215 440 2.04 
Mean Sulfadimethoxine 180 399 2.23 
11 Sulfadiazine 146 639 4.38 
12 Sulfadiazine 141 622 4.41 
13 Sulfadiazine 158 642 4.07 
14 Sulfadiazine 136 635 4.67 
15 Sulfadiazine 167 636 3.81 
Mean Sulfadiazine 149 635 4.27 
16 Sulfadimidine 23 147 6.55 
17 Sulfadimidine 44 229 5.20 
18 Sulfadimidine 34 121 3.57 
19 Sulfadimidine 34 159 4.71 
20 Sulfadimidine 22 121 5.49 
Mean Sulfadimidine 31 155 5.11 
21 Sulfaguanidine 352 249 0.71 
22 Sulfaguanidine 218 170 0.78 
23 Sulfaguanidine 236 199 0.84 
24 Sulfaguanidine 289 231 0.80 
25 Sulfaguanidine 360 273 0.76 
Mean Sulfaguanidine 291 224 0.78 
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2.5.3.3 Protein/macromolecular binding 
Ultrafiltration of yolk samples proved not to be possible due to clogging of material on 
the membrane. 
 
The ultrafiltration of the white samples indicated the following average protein binding;  
Sulfachloropyrazine 27 % 
Sulfadimethoxine 30 % 
Sulfadiazine - 31 % 
Sulfadimidine 5 % 
Sulfaguanidine 9 % 
 
The data on sulfadiazine can only be explained if a much lower recovery from the 
incurred total white samples occurred, than measured in the recovery experiments with 
added material. Therefore the absolute values of the protein binding experiments must 
be viewed with caution. Assuming however that in relative terms they are correct, the 
differences in protein binding percentages can not explain the observed differences in 
white/yolk ratios. Sulfadimidine and sulfaguanidine have a similar protein binding but 
differ considerably in white/yolk ratio, whereas sulfadimidine having a lower protein 
binding than sulfachloropyrazine and sulfadimethoxine has a much higher white/yolk 
ratio. 
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3 RESULTS AND DISCUSSION 
 
3.1  Introduction 
 
Furusawa (1999) makes the following statements on the reasons for drug residues in 
white and yolk and the distribution between of drugs between white and yolk. 
  
 Therefore, the drug content in egg yolk is a cumulative sum of the drug during the 
growth of the yolk. On the other hand, albumen synthesized in the cells of the magnum 
are secreted by this part of the oviduct (concentrated albumen). The albumen is then 
later diluted with water (plumping water) in the shell gland. Therefore the drugs 
presence in the albumen reflects closely the blood concentration during the substantial 
time (~10-13 h) required for albumen formation in the oviduct. This seems to agree with 
the hypothesis of passive diffusion of the drug across the albumen glandular epithelium 
and an equilibrium between the drug concentrations in blood and in the albumen in the 
oviduct. The drugs tested are transported as one soluble compound in blood. The 
relative contents of a drug in egg yolk or albumen depends on its relative solubility in 
lipid or water, respectively. The drugs having the property of lipid-solubility are found in 
much higher levels in egg yolk than in albumen, whereas those having water-solubility 
are found in higher concentrations in albumen than in yolk.” 
 
Furusawa (2001) later stated shortly “Large variations in the ratio of the contents of 
the drugs in egg yolk to that in albumen occur with different drugs. This variation 
should depend mainly on the relative lipid-solubility and water-solubility of the drug. 
Drugs that are lipid soluble, such as amprolium or nicarbazin are found in much 
higher concentrations in egg yolk than in albumen. In contrast, those that are water 
soluble, such as the sulfonamides, are found in a higher concentration in albumen 
than in egg yolk.” 
 
These statements nicely summarise the traditional approach to the subject of this 
study. Literature data and data out of our previous studies and the present one 
clearly indicate certain inconsistencies or mistakes in this concept. 
 
 57
Chapter 3 
3.2 Parameters studied 
 
To prove or disprove the concept outlined above, the distribution of sulfonamides 
between egg white and yolk was studied and the following physicochemical 
characteristics of the different substances were considered of possible importance for 
this distribution: 
• Lipid solubility  
• Distribution between the aqueous and organic phase (log p value) 
• pKa value 
• Protein binding  
 
3.2.1 Lipid solubility and partitioning coefficient in relation to white/yolk ratio 
The partitioning coefficients of the different sulfonamides obtained with dichloromethane 
as the organic phase have been given in Table 3. The white/yolk ratios have been given 
in Tables 5 and 6. Table 7 shows the direct comparison of P values at pH values 6.0 
and 7.6 and the white yolk ratios found in the two trials. The partitioning of the 
sulfonamides between dichloromethane and an aqueous buffer solution showed large 
differences between the different substances. Sulfadimethoxine shows (on average) the 
largest affinity for the organic phase and sulfaguanidine the least. The P or log P values 
 which are also indicator of the solubility in the organic phase  and the white/yolk 
ratios of the different sulfonamides given in Table 7 show no obvious relationship. 
Sulfadimethoxine, which has the highest P values, so the highest affinity for the organic 
phase and probably the highest lipid solubility, certainly has not the lowest white/yolk 
ratio, as would follow from the lipid solubility theory. Sulfanilamide having a low P value 
and lipid solubility should have had a high white to yolk ratio, if lipid solubility would 
have been the main driving force but it has a white/yolk ratio close to 1. Sulfaguanidine 
has an extremely low partitioning ratio and solubility in the organic phase. It does not 
have a correspondingly low white to yolk ratio, which also does not support lipid 
solubility as being the driving force for distribution of sulfonamides between white and 
yolk.  
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Table 7: Sulfonamides and their determined partitioning coefficients at pH 6.0 
and 7.6 and white/yolk ratios found in trials 1 and 2 
Sulfonamide P at pH 6.0
DCM/H2O 
P at pH 7.6
DCM/H2O 
Ratio white/yolk 
trial 1 
Ratio white/yolk 
trial 2 
Sulfisoxazole 0.92 0.0225 < 1.5 
SA 0.48 
 
Sulfachloropyrazine 4.17 0.114 3.13 2.67 
Sulfaquinoxaline 47 2.16 2.08  
Sulfamethoxazole 4.7 0.190 3.56  
Sulfadimethoxine 66 3.8 2.32 2.23 
Sulfadiazine 1.93 0.215 9.27 4.27 
Sulfamerazine 5.1 1.228 8.77  
Sulfadimidine 9.4 5.5 2.88 5.11 
Sulfapyridine 2.68 2.49 ? (SA 0.51)  
Sulfanilamide 0.092 0.093 1.09  
Sulfaguanidine 0.00183 0.00187 ? (<3) 0.78 
 
The data in Table 7 thus show no obvious general relationship between P value and 
white to yolk ratio.  
Gorla et al. (1997) and Furusawa (1999, 2001) both state, that lipid soluble drugs will 
predominantly be present in yolk and water-soluble drugs predominantly in white. The 
results on the lipid soluble doxycycline in contrast to the less lipid soluble 
oxytetracycline (see Table 1) as well as the results presented above on the 
sulfonamides do not fully support this statement.  
So - generally spoken - lipid solubility of a drug, when given to laying hens, on its own 
does not determine the white/yolk ratio of that drug. 
 
3.2.2 pKa value and white/yolk ratio 
Table 8 shows the calculated ratio of the measured partitioning ratios at pH values 6.0 
and 7.6 (Table 4) and for comparison the white/yolk ratios measured in the two trials 
(Tables 5 and 6). The pH values 6.0 and 7.6 were chosen for this determination as they 
mimic the pH values of yolk and white in freshly laid eggs.  
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Table 8: Ratio of the partitioning coefficients measured at pH values 6.0 and 7.6 
and the white/yolk ratios.  
 
Sulfonamide 
 
pKa 
Ratio of P values measured 
at pH 6.0 and 7.6 
White/yolk 
ratio trial 1 
White/yolk 
ratio trial 2 
Sulfisoxazole 4.7 40.9 < 1.5 
SA 0.48 
 
Sulfachloropyrazine 5.1 36.6 3.13 2.67 
Sulfaquinoxaline 5.5 21.8 2.08  
Sulfamethoxazole 5.9 24.7 3.56  
Sulfadimethoxine 6.3 17.4 2.32 2.23 
Sulfadiazine 6.5 9.0 9.27 4.27 
Sulfamerazine 7.0 4.2 8.77  
Sulfadimidine 7.5 1.7 2.88 5.11 
Sulfapyridine 8.4 1.08 ? (SA 0.51)  
Sulfanilamide 10.5 0.99 1.09  
Sulfaguanidine 11.3 0.98 ? (<3) 0.78 
 
The ratio of the P values at pH 6.0 and 7.6 shows quite a good correlation with the pKa 
of the different sulfonamides. This indicates that at each pH of the aqueous phase, only 
the uncharged molecule seems to contribute to the observed distribution between the 
organic phase and aqueous phase. The ratio of the distributions observed at the two 
different pH values shows data very similar to those, calculated for a distribution of 
uncharged molecules between aqueous phases with the different pH values separated 
by a semi-permeable membrane.  
Such a relationship between pKa of various drugs and pH values of different aqueous 
phases has been proven accurate for the explanation of a number of observed 
distribution ratios. The successful explanation of distribution of different drugs in 
different physiological systems, such as plasma/gastric juice, plasma/cerebrospinal 
fluid, plasma/red cells and plasma/milk has been outlined in the introduction.  
The ratio of the P values at pH 6.0 (yolk) and 7.6 (white) and the white/yolk ratio 
observed for the 11 different sulfonamides tested (Table 8) shows no obvious (linear) 
relationship. The white/yolk ratio of the 11 sulfonamides seems to be non-related to 
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their pKa value.  The assumption that the egg can be considered as two aqueous 
phases with different pH values separated by a semi-permeable membrane and 
distribution of the sulfonamides between white and yolk being only governed by 
distribution of the uncharged sulfonamide molecule, can thus not be substantiated. 
Blom (1975) tried to explain the distribution between plasma and egg white of the three 
sulfonamides studied by him on the basis of their pKa values and could not draw an 
unambiguous conclusion.  
Apparently the distribution of sulfonamides between plasma and white and between 
white and yolk is not only  or may be not at all - governed by diffusion or passage of 
the uncharged molecule only. 
 
3.2.3 Protein/macromolecular binding and white/yolk ratio 
Numerous drugs including sulfonamides have been observed to bind to (plasma) 
proteins. This binding has both been observed in vivo and in vitro: thus either after 
treatment of an individual with a drug or after adding a drug to a blank plasma, the 
plasma sample contained both bound and free drug. Protein binding measured in vivo 
has the large advantage that it is governed by those process occurring in the living 
object, where as in vitro artefacts not occurring in life might show up. 
The results obtained by measuring in vivo protein binding of five sulfonamides in egg 
white and the observed white/yolk ratios are given in Table 9. 
 
Table 9: Comparison of protein binding and white/yolk ratio 
Sulfonamide Protein binding % White/yolk ratio 
Sulfachloropyrazine 27 2.67 
Sulfadimethoxine 30 2.23 
Sulfadiazine -31 4.27 
Sulfadimidine 5 5.11 
Sulfaguanidine 9 0.78 
 
No obvious relationship between measured in vivo protein binding in egg white and 
white/yolk ratio is evident from the data. Blom (1975) measured both in vivo and in 
vitro binding of three sulfonamides in egg white. No relationship between protein 
binding and white to yolk ratio could be deduced from his data. Nevertheless some 
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kind of active binding must take place in oviduct or albumen as Furusawa (1999) 
reported lower concentrations of spiramycine, oxytetracycline and sulfamonomethoxine 
in blood than in oviduct tissue and albumen. He nevertheless assumes that passive 
diffusion from blood to albumen occurs and that water or lipid solubility is the major 
determining factor. On the other hand (Furusawa personal communication, 2000) he 
believes, that protein binding (both rate of binding and amount of binding material) can 
have a major impact on distribution of the drug in the body and within the egg. 
 
3.3 Other (unexplained) observations 
 
Spiramycine (Yoshida et al., 1971; Roudaut and Moretain, 1990) as well as the 
quinolones, oxolinic acid (Roudaut and Boisseau, 1990) and flumequin (van Leeuwen 
and van Gend, 1989) show a longer persistence of residues in egg white than in yolk. 
McCracken et al. (2001) fed furazolidone to laying hens during 8 days and measured 
both the parent compound and a major metabolite (AOZ) in egg white as well as in 
yolk. During treatment they found all compounds in all compartments but at 11 days 
after withdrawal no parent furazolidone could be detected (as can be anticipated) in 
either yolk or egg white, but the metabolite was present still in both egg white and yolk. 
The presence of a drug or metabolite in both white and yolk suggests storage of it at 
some other place in the body and redistribution via the blood (or lymphatic system). 
The presence of a compound in white only suggests more specifically a kind of storage 
in the oviduct tissue (or elsewhere in the body) together with a strong affinity of the egg 
white for it (or vice versa). Protein binding of some kind is the most likely candidate for 
this.  
Furusawa (1999) observed quite high levels of spiramycine in oviduct tissue much 
higher than in blood or albumen -, which he suggested (Furusawa personal 
communication, 2000) to be caused by some kind of protein binding. This high binding 
might in turn be responsible for the prolonged half-live in egg white observed by others. 
Furusawa (1999) also observed high levels of oxytetracycline and 
sulfamonomethoxine in oviduct tissue, but these were comparable to levels in 
albumen. 
Furusawa and Kishida (2002) fed five different sulfonamides (sulfadiazine, 
sulfadimidine, sulfamonomethoxine, sulfamethoxazole and sulfaquinoxaline) at 100 
mg/kg diet to laying hens for seven days and then measured levels in plasma, liver, 
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muscle, ovary, the magnum fraction of the oviduct and the shell gland fraction. They 
found considerable differences in the distribution over the different tissues between the 
five sulfonamides tested.  Plasma levels were (much) higher than levels for all other 
tissue with the exception of sulfadimidine in which case plasma and liver contents were 
about equal. Sulfadiazine, which in our experiments had a considerable white to yolk 
ratio and to a lesser extent sulfaquinoxaline, showed in their experiment a similar 
content in oviduct (magnum) tissue and ovary. Sulfadimidine and sulfamethoxazole 
showed a higher content in ovary tissue than in magnum tissue which contradicts our 
white to yolk ratios of about 3.  The results from Furusawa and Kishida (2002) on 
distribution of sulfonamides within the tissues of the laying hen, thus do not explain the 
white to yolk ratios found in our experiments. 
 
3.4 Some points still to be tackled 
  
1. Determination of the complex or form in which drugs are transported (via the 
blood) to and deposited in the ovary. 
2. Determination how and at what time and place drugs enter the egg white: during 
deposition of egg white or (also) during plumping or even during calcification of 
the egg. Donoghue et al. (2000) have proven the transfer of oxytetracycline 
during plumping, but more data should be gathered. 
3. Determination of pH values at the micro-scale at those places where processes 
really occur and not only in the bulk of the phase. This would help to ascertain 
whether indeed only the non-ionised form of the molecules is involved in the 
different processes. 
4. Study of possible (re) distribution processes of drugs between egg white and yolk 
during egg- and shell-formation.  
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3.5 Overall conclusions 
 
1. The processes of yolk formation and deposition and the processes of egg white 
formation and deposition govern the shape of the residue curves in eggs (white and 
yolk) when drugs are given to or withdrawn from laying hens.  
2. The eleven tested sulfonamides all show considerable levels in egg white despite 
their often high affinity for the organic phase, which  according to the lipid solubility 
concept - would suggest the predominant deposition in yolk. 
3. The physiochemical characteristics measured: log P (at two different pH values), 
pKa and protein binding fail to predict or explain the observed distribution of the 
eleven sulfonamides between egg white and yolk when administered to laying 
hens. 
4. The concept that concentrations of sulfonamides in egg white and yolk are directly 
related to and can be explained or predicted by one or two physicochemical 
measurements or characteristics is too simplistic. In other words, egg white and 
yolk are not two liquid phases separated by a semi-permeable membrane 
exhibiting equilibrium in contents of sulfonamides between them. 
5. The complicated reality is that levels in yolk depend on both yolk deposition and 
solubility or affinity of the drug for the lipid phase. Levels in egg white probably 
depend on circulating plasma levels and specific binding of the drug to protein(s) in 
plasma and egg white and the affinity constants of that binding. Thus two non-
directly related processes are taking place. 
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